Get the Stockscreener App
56.36
2.60%
1.43
Haemonetics Corp stock is traded at $56.36, with a volume of 536.63K.
It is up +2.60% in the last 24 hours and down -10.99% over the past month.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
See More
Previous Close:
$54.93
Open:
$55.44
24h Volume:
536.63K
Relative Volume:
0.64
Market Cap:
$2.62B
Revenue:
$1.32B
Net Income/Loss:
$175.44M
P/E Ratio:
15.49
EPS:
3.6395
Net Cash Flow:
$308.08M
1W Performance:
-0.53%
1M Performance:
-10.99%
6M Performance:
+15.63%
1Y Performance:
-11.31%
1-Day Range:
$54.84
$57.11
1-Week Range:
$53.88
$57.72
52-Week Range:
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
Name
Haemonetics Corp
Sector
Industry
Phone
(781) 848-7100
Address
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
56.36 | 2.62B | 1.32B | 175.44M | 308.08M | 3.6395 |
ABT
Abbott Laboratories
|
102.67 | 178.41B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
328.59 | 125.84B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.65 | 111.25B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.75 | 93.26B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.08 | 46.17B | 6.07B | 1.06B | 1.34B | 1.8063 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Downgrade | Needham | Buy → Hold |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Aug-11-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-08-25 | Reiterated | Barrington Research | Outperform |
| Aug-08-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| Jun-26-25 | Initiated | Robert W. Baird | Outperform |
| Feb-07-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-24 | Initiated | JP Morgan | Overweight |
| Nov-08-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-13-24 | Initiated | CL King | Buy |
| Sep-11-24 | Initiated | BofA Securities | Neutral |
| Sep-10-24 | Initiated | BTIG Research | Buy |
| Jun-12-24 | Upgrade | Needham | Hold → Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jan-27-22 | Downgrade | Needham | Buy → Hold |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-17-21 | Resumed | Raymond James | Outperform |
| Jun-17-21 | Initiated | Citigroup | Buy |
| May-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Apr-20-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Feb-03-21 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jan-21-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-05-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-31-20 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Jan-10-20 | Initiated | Needham | Buy |
| Aug-07-19 | Reiterated | Barrington Research | Outperform |
| May-14-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-19 | Reiterated | Barrington Research | Outperform |
| Aug-09-18 | Reiterated | Barrington Research | Outperform |
| Feb-07-18 | Reiterated | Barrington Research | Outperform |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-08-17 | Reiterated | Barrington Research | Outperform |
| Aug-08-17 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-13-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-07-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-08-16 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Nov-07-16 | Reiterated | The Benchmark Company | Hold |
| Sep-20-16 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Aug-15-16 | Downgrade | Sidoti | Buy → Neutral |
| Aug-02-16 | Reiterated | Jefferies | Buy |
| Aug-02-16 | Reiterated | The Benchmark Company | Hold |
View All
Haemonetics Corp Stock (HAE) Latest News
Allspring Global Investments Holdings LLC Sells 121,063 Shares of Haemonetics Corporation $HAE - MarketBeat
Automatic Blood Bag Tube Stripper Market Is Going to Boom | Terumo - openPR.com
Haemonetics: FDA Label Expansion and New Product Launches Poised to Reignite Vascular Closure Growth by FY27 - TipRanks
FDA Expands Approval for Haemonetics' (HAE) VASCADE MVP XL Syste - GuruFocus
Is Haemonetics (HAE) Leveraging VASCADE MVP XL’s FDA Expansion To Deepen Its EP Moat? - simplywall.st
Haemonetics wins FDA nod for expanded vascular closure system use - Investing.com
Haemonetics Wins FDA Approval to Expand Label for VASCADE MVP XL - marketscreener.com
FDA expands use of Haemonetics device in atrial fibrillation care - Stock Titan
Haemonetics Corp. Experiences Revision in Stock Evaluation Amid Market Challenges - marketsmojo.com
Haemonetics stock maintained at Buy by BTIG on FDA label expansion - Investing.com South Africa
Haemonetics: FDA approves expanded labeling for VASCADE MVP XL system - TipRanks
Assenagon Asset Management S.A. Sells 99,083 Shares of Haemonetics Corporation $HAE - MarketBeat
Short Interest in Haemonetics Corporation (NYSE:HAE) Decreases By 29.7% - MarketBeat
Vanguard disaggregates holdings after internal realignment (NYSE: HAE) - Stock Titan
Update Recap: What drives Haemonetics Corporations stock price2026 Breakouts & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Q2 EPS Estimates for Haemonetics Boosted by Zacks Research - MarketBeat
A Look At Haemonetics (HAE) Valuation After Recent Share Price Weakness - simplywall.st
Q3 EPS Estimates for Haemonetics Increased by Zacks Research - MarketBeat
HAE Price Today: Haemonetics Corporation Stock Price, Quote & Chart - mexc.co
Haemonetics Corp stock faces uncertainty amid lack of fresh catalysts in blood management sector - AD HOC NEWS
Why Haemonetics Stock Is Suddenly Bouncing Back - TipRanks
Hospital Solutions launch from Haemonetics aims to transform patient care standards - Traders Union
Haemonetics Corp Stock Surges on Strong Momentum Amid Plasma and Hemostasis Demand - AD HOC NEWS
Don't Get Too Worked Up Over Haemonetics's Earnings - Yahoo
What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year - AOL.com
Haemonetics Corp. Forms Death Cross, Signaling Potential Bearish Trend Ahead - marketsmojo.com
HAE Stock Price, Quote & Chart | HAEMONETICS CORP/MASS (NYSE:HAE) - ChartMill
Here's Why Haemonetics (HAE) is a Strong Value Stock - Yahoo Finance
Haemonetics Corporation (HAE) Q3 performance prompts Baird model update, price target falls to $81 - MSN
London Co. of Virginia Decreases Stake in Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corporation (HAE) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Haemonetics Corporation $HAE Shares Purchased by Invenomic Capital Management LP - MarketBeat
Haemonetics Corp Stock (ISIN: US4041191090) Faces Pressure Amid Hospital Recovery and Debt Concerns - AD HOC NEWS
Haemonetics Corporation (NYSE:HAE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Haemonetics (HAE) Quietly Rewiring Its Margin Profile Through NexSys PCS And Hospital Acquisitions? - simplywall.st
Does Haemonetics' (HAE) Hospital Rebound and NexSys Expansion Reframe Its Competitive Positioning? - Yahoo Finance
Aristotle Capital Boston LLC Increases Stock Position in Haemonetics Corporation $HAE - MarketBeat
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Cuts Target Price to $70 - 富途牛牛
Haemonetics Corp Stock (ISIN: US4041191090) Expands Hospital Portfolio Amid Valuation Discount and A - AD HOC NEWS
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Maintains Target Price $70 - 富途牛牛
Haemonetics Expands Hospital Portfolio As Investors Weigh Growth And Valuation - simplywall.st
Haemonetics Corp. Experiences Revision in Its Stock Evaluation Amid Market Dynamics - marketsmojo.com
Haemonetics Corporation $HAE Shares Sold by Schroder Investment Management Group - MarketBeat
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now? - Yahoo Finance
Haemonetics Corporation $HAE Shares Acquired by Barrow Hanley Mewhinney & Strauss LLC - MarketBeat
Haemonetics price target lowered to $70 from $75 at Citi - TipRanks
Citigroup Maintains Neutral Rating on Haemonetics (HAE), Lowers Price Target | HAE Stock News - GuruFocus
Citigroup Issues Pessimistic Forecast for Haemonetics (NYSE:HAE) Stock Price - MarketBeat
Haemonetics launches recruitment drive to expand clinical support roles - Traders Union
HAE SEC FilingsHaemonetics Corp Mass 10-K, 10-Q, 8-K Forms - Stock Titan
Haemonetics Corp Stock (HAE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):